ReviewBiomedicines2022
Immunotherapeutic Approaches for Glioblastoma Treatment.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Breaking Barriers: Advancements in CNS Drug Delivery for Glioblastoma.Medical sciences (Basel, Switzerland) · 2026Review
- Biomarkers of immunotherapy response in neuro-oncology.Neuro-oncology advances · 2025Review
- Patient-Derived Glioblastoma Explants Empower Rapid and Personalized Drug Assessment: Harnessing the Potential of 3D Perfusion Bioreactors in Glioblastoma Drug Discovery.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Review
- DNAJC1 facilitates glioblastoma progression by promoting extracellular matrix reorganization and macrophage infiltration.Journal of cancer research and clinical oncology · 2024Article
- NR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human glioma.Frontiers in immunology · 2023Article
- Emerging Biomarkers for Immunotherapy in Glioblastoma.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Glioblastoma remains a challenging disease to treat, despite well-established standard-of-care treatments, with a median survival consistently of less than 2 years. In this review, we delineate the unique disease-specific challenges for immunotherapies, both brain-related and non-brain-related, which will need to be adequately overcome for the development of effective treatments. We also review current immunotherapy treatments, with a focus on clinical applications, and propose future directions for the field of GBM immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.